Innovation4Alpha Se1Ep3 – Investing in What You Know

If you’ve been around AngelMD for any length of time, you’ve heard us talking about investing in what you know. It’s the key that makes AngelMD investment so strong.

In this episode, AngelMD CEO Tobin Arthur discusses the topic, and helps to define the ways to use your own knowledge to make investment decisions.

Continue reading

New Startups on AngelMD – May 2019

The following companies all joined AngelMD in May of 2019. Follow the companies of your choice to stay up to date with their progress and activity.

Medical Device

Health IT

Diagnostics

Practice Management

EMR

Telemedicine

Pharmaceutical

Patient Care

Consumer Product

Diagnostics

Continue reading

Innovation4Alpha Se1Ep2 – Financial Literacy

In this week’s episode, Tobin and Jeff discuss the methods that they use to continually increase their financial literacy. Make sure to check out the show notes below to find links to resources mentioned in the podcast.

Continue reading

New Startups on AngelMD – April 2019

Each of the following companies joined AngelMD during the month of April, 2019. Make sure to follow the companies that are operating within your areas of interest in order to stay up to date with their progress.

Artificial Intelligence

Bio Science

Medical Device

Diagnostics

Consumer Product

Patient Care

EHR/EMR

Pharmaceutical

Cost Reduction

Telemedicine

Mobile Health

Continue reading

Artoss, Inc. Awarded FDA Clearance

Congratulations are in order for AngelMD portfolio company Artoss, Inc. Artoss is a medical device company that has developed NanoBone, an advanced synthetic bone graft technology.

NanoBone was tested alone (without addition of autograft or bone marrow aspirate) in the ASTM International standardized animal model and found to be equivalent to the “gold standard” autograft in fusion rate.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “The ASTM standard animal model for lumbar intertransverse process spinal fusion is a very challenging model designed to replicate clinically relevant fusion rates for iliac crest autograft in the posterolateral spine.

A majority of bone void fillers must be mixed with autograft in order to achieve equivalent fusion rates to autograft alone. We’re pleased to offer surgeons a synthetic alternative to autograft that does not require mixing with autograft or bone marrow. Using a synthetic bone void filler alone offers significant cost savings to hospitals. NanoBone stands alone.”

“NanoBone Bone Graft used as a standalone in posterolateral spinal fusion represents asignificant advancement in patient care.” said J. Eric Gee, M.D. “Eliminating the need to mix synthetic graft with autograft or to harvest and concentrate bone marrow aspirate will save time and money as well as streamline operating room procedures.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

Continue reading